Summary of Pacific Biosciences of California FY Conference Call Company Overview - **Company**: Pacific Biosciences of California (NasdaqGS:PACB) - **Event**: FY Conference Call on March 02, 2026 Key Industry Insights - **Sequencing Technology**: The company focuses on long-read sequencing technology, which is gaining traction in clinical markets, particularly for whole genome sequencing in rare diseases and carrier screening applications [4][8][52] - **Competitive Landscape**: The company positions itself against competitors like Illumina, emphasizing its unique capabilities in long-read sequencing and the ability to provide comprehensive genomic data [10][11][15] Financial Performance and Projections - **2025 Performance**: The company reported a 55% growth in clinical consumables shipments, indicating strong demand and market penetration [32][44] - **2026 Guidance**: The company anticipates continued growth in clinical revenue, driven by expanding customer projects and the introduction of new products like SPRQ-Nx chemistry [6][41][66] - **Academic Market Challenges**: The U.S. academic market remains challenging, with a significant revenue gap of approximately $30 million to recover, but the company expects to grow outside the U.S., particularly in Europe [16][22][24] Product Developments - **SPRQ-Nx Chemistry**: This new product is expected to enhance performance, increase throughput, and lower costs for customers, making it competitive with short-read sequencing [5][6][73] - **Revio Utilization**: Current average utilization of Revio systems is around 20%, with expectations to increase as projects scale and the new chemistry is adopted [89][94] Market Opportunities - **Rare Diseases**: The primary focus area, with an estimated 300-400 million patients globally, highlighting the need for improved diagnostic capabilities [52][54] - **Carrier Testing**: The PureTarget 2.0 assay is gaining traction, allowing customization for specific genes across the genome [56] - **Newborn Screening**: The company is involved in initiatives in Thailand to integrate whole genome sequencing into newborn screening programs, showcasing the economic value of sequencing [57][60] Strategic Priorities - **Higher Throughput Sequencer Development**: A key priority to enable larger clinical testing laboratories to adopt the technology [65] - **Health Economics Studies**: Focus on demonstrating the cost-effectiveness of HiFi sequencing compared to other technologies [66][70] Conclusion - **Strong Positioning**: The company believes it is in a better position than ever, with a comprehensive product portfolio, improving financial metrics, and a strong global presence [96][97] - **Future Outlook**: The leadership anticipates significant growth opportunities in 2026 and beyond, with a focus on expanding clinical applications and market share [99][101]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [7][27] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [7][30] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and for the full year, it was also 40%, compared to 33% in 2024 [31][24] - Non-GAAP operating expenses decreased to $56.2 million in Q4 2025, down 18% year-over-year, and for the full year, they were $229.9 million, down from $289.2 million in 2024 [32][24] - Cash burn improved from $214 million in 2023 to $105 million in 2025, with approximately $280 million in cash and investments at year-end [25][34] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by an increase in the installed base and consistent system utilization [27][28] - Instrument revenue rose 13% in Q4 to $17.3 million, primarily due to increased shipments of Vega systems [28] - For the full year 2025, consumables revenue increased 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [30] Market Data and Key Metrics Changes - Revenue from the Americas increased 3% to $20.7 million in Q4 2025, while Asia Pacific revenue rose 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [29][10] - EMEA's strong growth was attributed to increased Vega instrument shipments and higher Revio consumables as clinical customers transitioned from pilot testing to broader adoption [11][29] Company Strategy and Development Direction - The company aims to enhance the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells, targeting increased market penetration [37] - Focus areas include accelerating clinical adoption in rare disease, oncology, and carrier screening, as well as enabling population-scale sequencing studies [37] - The company plans to leverage AI to unlock biological insights from multi-omic HiFi data [37] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued growth in clinical markets, particularly in rare disease and whole genome sequencing, despite a challenging academic funding environment [11][54] - The outlook for 2026 projects revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint [34] - Management expects non-GAAP gross margin to improve by 100-400 basis points in 2026, driven by a higher consumables mix and the introduction of SparkNex [35] Other Important Information - The company sold its short-read sequencing assets for net proceeds of approximately $48 million, strengthening its balance sheet and extending its cash runway [26] - The company is committed to supporting existing customers during the transition period following the divestment of short-read assets [26] Q&A Session Summary Question: What should we expect for Revio pull-through and consumables growth? - Management expects SparkNex to lower sample costs, likely increasing utilization and expanding market share, while maintaining pull-through in the range of $225K-$250K [41][43] Question: What is the outlook for clinical growth outside the U.S.? - Management sees strong growth in clinical markets, particularly in EMEA, with significant movement from pilot phases to production [53] Question: Where are the biggest opportunities for OpEx reduction? - Management plans to focus on managing G&A expenses and R&D while continuing to reduce production costs through insourcing [66][68] Question: What impact will the short-read divestment have on costs? - Management indicated that while there won't be substantial additional costs taken out immediately, the divestment will provide a tailwind to gross margin over time [72] Question: How does long-read sequencing compare to standard care in terms of cost? - Long-read sequencing is expected to provide better diagnostic yield, faster turnaround times, and lower overall costs by consolidating multiple tests into one [74]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [7][26] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [7][30] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and also increased from 33% in 2024 to 40% in 2025 [31][23] - Non-GAAP operating expenses decreased from $355 million in 2023 to $230 million in 2025, a 35% reduction [23][32] - Cash burn improved from $214 million in 2023 to $105 million in 2025, representing a 51% improvement [24] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by an increase in the installed base and consistent system utilization [26][30] - Instrument revenue increased 13% in Q4 2025 to $17.3 million, primarily due to an increase in Vega systems [27] - For the full year 2025, consumables revenue grew 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [30] Market Data and Key Metrics Changes - In Q4 2025, Americas revenue increased 3% to $20.7 million, Asia Pacific revenue increased 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [10][29] - EMEA's strong growth was attributed to increased Vega instrument shipments and higher Revio consumables as clinical customers shifted to broader clinical adoption [11][29] Company Strategy and Development Direction - The company aims to improve the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells [38] - Focus on accelerating clinical adoption in rare disease, oncology, and carrier screening, while enabling population-scale sequencing studies [38] - The strategy includes leveraging AI to unlock biological insights and driving innovation in sequencing technology [38] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 revenue to be in the range of $165 million to $180 million, representing approximately 8% growth at the midpoint [11][34] - The company anticipates continued pressure from the academic funding environment, particularly in the Americas, impacting capital spending [34][35] - Management is optimistic about the growth in clinical markets, especially in EMEA, despite the challenges in the academic sector [53] Other Important Information - The company sold its short-read sequencing assets for net proceeds of approximately $48 million, strengthening its balance sheet [25] - The introduction of SparkNex is expected to enhance gross margins and improve the overall financial profile [21][23] Q&A Session Summary Question: What should we expect OUS to do this year from a clinical growth perspective? - Management noted strong growth in clinical markets, particularly in rare disease and whole genome sequencing, especially in EMEA, with customers moving from pilot phases to production [53] Question: Where's the biggest opportunity to reduce OpEx spending this year? - Management indicated a focus on managing G&A expenses and R&D while maintaining critical programs, with a goal to reduce non-headcount-related spending [66] Question: Did you see any budget flush, particularly from Europe in full Q25? - Management did not observe significant budget flush but noted some opportunistic purchasing [51][52]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [5][25] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [5][29] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and for the full year, it was also 40%, compared to 33% in 2024 [30][22] - Non-GAAP operating expenses decreased to $56.2 million in Q4 2025, down 18% year-over-year, and for the full year, they were $229.9 million, down from $289.2 million in 2024 [31][22] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by a growing installed base and consistent system utilization [25][6] - Instrument revenue rose 13% in Q4 2025 to $17.3 million, primarily due to increased shipments of Vega systems [26] - For the full year 2025, consumables revenue increased 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [29] Market Data and Key Metrics Changes - Revenue from the Americas increased 3% to $20.7 million in Q4 2025, while Asia Pacific revenue grew 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [27][28] - The strong growth in EMEA was attributed to increased clinical adoption and higher shipments of Vega instruments [28] Company Strategy and Development Direction - The company aims to improve the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells, targeting increased market penetration [37] - Focus areas include accelerating clinical adoption in rare disease, oncology, and carrier screening, as well as enabling population-scale sequencing studies [37] - The company plans to leverage AI to unlock unique biological insights from multi-omic HiFi data [37] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued growth in clinical markets, particularly in rare disease and whole genome sequencing, despite a challenging academic funding environment [9][52] - The outlook for 2026 projects revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint [33] - Management expects non-GAAP gross margin to improve by 100-400 basis points in 2026, driven by a higher consumables mix and the introduction of SparkNex [34] Other Important Information - The company ended 2025 with approximately $280 million in cash and investments, down from $389.9 million at the end of 2024 [23][33] - The recent sale of short-read sequencing assets for approximately $48 million is expected to strengthen the balance sheet and extend the cash runway [24] Q&A Session Summary Question: What should we expect OUS to do this year from a clinical growth perspective? - Management noted strong growth in clinical markets, particularly in EMEA, with many customers moving from pilot testing to broader clinical adoption [52] Question: What is the biggest opportunity to reduce OpEx spending this year? - Management indicated a focus on managing G&A expenses and R&D while maintaining funding for critical programs [66] Question: Did you see any budget flush, particularly from Europe in full Q25? - Management did not observe significant budget flush but noted some opportunistic purchasing [51]